OUR QUEST

Advancing medicines
Solving therapeutic problems
Improving lives

12 years. 2+ billion doses and counting.

Our pipeline of medicines aims to overcome barriers that patients face with existing treatment options and provide new paradigms for treating critical and complex conditions.¹

See our pipeline

OUR QUEST

Deliver clinical and therapeutic advances

2B+ doses consumed. 200+ patents provide strong intellectual property.

Aquestive is the worldwide leader in delivering trusted, quality medications on oral film. Every medicine is different, so Aquestive follows a drug-by-drug approach for harnessing PharmFilm® technology to achieve target product profiles and clinical improvement goals.

Learn about PharmFilm^® technology

Pipeline

Aquestive Therapeutics is the undisputed leader in developing and delivering medications via film, through our proprietary PharmFilm® technology. We’ve used our expertise to create a robust, proprietary CNS and complex molecule portfolio.

Learn about the medicines we’re reinventing to improve treatment options for patients.

See our pipeline

Innovative Drug Delivery

PharmFilm® is a versatile, high-performance drug delivery technology that can be uniquely tailored to achieve a desired product profile with optimized absorption, bioavailability, and onset of action.

See how Aquestive is changing drug delivery to deliver meaningful clinical and therapeutic advances.

Learn about PharmFilm^® technology

Commitment to Epilepsy

Our innovations in oral drug delivery aim to improve the treatment experience for patients with epilepsy and their caregivers who struggle with difficult or invasive modes of administration, complex treatment regimens, and inconsistent dosing and drug delivery.² Our efforts to help patients and families extend beyond the clinic.

Find out how

We are committed to you

Click here to view a message from Chief Executive Officer, President and Director of Aquestive Therapeutics, Inc. about COVID-19

Advancing medicines

Solving therapeutic problems

Improving lives

Aquestive is a pharmaceutical company that advances and commercializes medicines to solve therapeutic problems and meaningfully improve people’s lives. We apply innovative drug delivery technology and scientific expertise to redesign important medicines. Our initial focus, supported by our current approved products and late-stage pipeline, is to improve medications and outcomes for patients with central nervous system (CNS) conditions.

Our success is proven

2B+

PharmFilm® doses consumed by patients

200+

Worldwide patents

Continents where our products are sold

Aquestive works hand-in-hand with our partners to address their toughest challenges—enhancing existing molecules and providing a development platform for new ones. We have comprehensive capabilities to advance medicines from pipeline to market. Partners can rely on our scientific and regulatory expertise, integrated development capabilities, and world-class clinical and commercial manufacturing operations. More than 2 billion commercial doses have been delivered with our PharmFilm® technology.

News Articles

Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) In Development for Treatment of Allergic Reactions Including Anaphylaxis

First healthy volunteer dosed in a Phase 1 study of AQST-108 for the treatment of allergic reactions including anaphylaxis Pharmacokinetic and pharmacodynamics data expected in fourth quarter 2020 WARREN, N.J. , Aug. 20, 2020 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc.

Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis

Finalizing preparations for pharmacokinetic (PK) clinical trials of AQST-108 First planned PK clinical trial expected to begin during the third quarter of 2020 WARREN, N.J. , Aug. 10, 2020 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on

Aquestive Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update: AQST-108 Progress Remains On Track; Libervant PDUFA Goal Date Approaches

Generated 59% year-over-year revenue growth for Sympazan ® (clobazam) FDA completed safety review of IND for AQST-108 (epinephrine) and approved commencement of first planned pharmacokinetics (PK) clinical trials Continues to advance Libervant™ (diazepam) through FDA review and on-going

Newsroom

References

1. Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013;3(2):67–76.

2. Haut SR, Seinfeld S, Pellock J. Benzodiazepine use in seizure emergencies: a systematic review. Epilepsy Behav. 2016;63:109–117.

Please complete this form:

Full name*
Email address*
Phone number*
What is your question?*
To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing info@aquestive.com or by calling 1-908-941-1900.
Subscribe
- I would like to receive information updates regarding products and services from Aquestive, and information about Aquestive-sponsored clinical trials.

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

Full name*
Email address*
Street Address*
City*
Zip Code*
Phone number*
Tell us how we can help your brand
Send me a kit
- Send me a PharmFilm® demonstration kit
I am interested in:
- Commercializing an existing product
- Commercializing a product in development
- Investment opportunities
To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.
Subscribe
- I would like to receive marketing updates regarding products and services from Aquestive Therapeutics.

Please complete this form:

Full name*
Email address*
Phone number*
What is your question?*
In what clinical trial are you interested?
To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing clinicaltrials@aquestive.com.
Subscribe
- I would like to receive information updates regarding products and services from Aquestive, and information about Aquestive-sponsored clinical trials.

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

Full name*
Email address*
Phone number*
What is your question?*
To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.
Subscribe
- I would like to receive information updates regarding products and services from Aquestive, and information about Aquestive-sponsored clinical trials.

Please complete the form below and click submit to receive a copy of “The Art of LGS Book.”

First Name*
Last Name*
Email Address*
Phone Number*
Role within the Epilepsy Community*
- Patient/Caregiver
- HCP
- Other
Tell us how we can assist you
- By providing my contact information, I agree that Aquestive Therapeutics (“Aquestive”) can use such information for its marketing database and that Aquestive and its agents may contact me by mail or email to provide information about Aquestive or its products or services. I understand that my contact information will not be sold to third parties, other than in the event Aquestive or its affiliates are sold. I understand that I have the right to opt-out of the database and have my information removed from the database at any time. Instructions on how to be removed from the database will be included in any future communications sent to me by Aquestive. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing lgsart@aquestive.com.